Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Association Between Bilateral Intermediate Cervical Plexus Block and Salivary Biomarkers of Surgical Stress Response Following Total Thyroidectomy

20. juli 2026 oppdatert av: Antonija Mihelcic, University Hospital Dubrava

The aim of this study is to evaluate how an ultrasound-guided bilateral intermediate cervical plexus block affects the surgical stress response in individuals undergoing total thyroidectomy. The primary objective is to quantify this physiological response through the analysis of specific stress and inflammatory biomarkers collected from the participants' saliva.

The clinical trial will encompass a total of 48 patients, randomized equally into two distinct cohorts of 24 participants each. The control group will undergo standard total intravenous anesthesia (TIVA), whereas the experimental group will receive the bilateral intermediate cervical plexus block in combination with the TIVA protocol.

It is hypothesized that integrating this regional nerve block with total intravenous anesthesia will significantly attenuate the surgical stress response, evidenced by a reduction in salivary biomarker concentration, compared to utilizing TIVA alone during thyroid surgery.

Validating this hypothesis would offer robust scientific evidence to advocate for the routine integration of the bilateral intermediate cervical plexus block into standard anesthetic practices for total thyroidectomy. Ultimately, this approach aims to minimize perioperative stress and facilitate a more rapid postoperative recovery for patients.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

48

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • ASA I or ASA II
  • euthyroid status
  • signed informed consent

Exclusion Criteria:

  • patients who refuse to sign the informed consent form
  • infection at the block injection site
  • hypersensitivity or contraindications to the medication used in the study
  • hypo/hyperthyroidism at the time of surgery
  • presence of substernal goiter
  • additional surgical interventions during the procedure
  • history of previous neck surgery or radiation
  • coagulopathy
  • uncontroled respiratory disease
  • diabetes mellitus
  • autoimune disease
  • chronic corticosteroid therapy
  • smokers
  • pregnant women

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: TIVA alone
Eksperimentell: TIVA + bilateral intermediate cervical plexus block with 0,25% levobupivacaine

Following the induction of general anesthesia in the study group, an ultrasound-guided bilateral intermediate cervical plexus block will be performed.

The cervical plexus is visualized on the screen as a small cluster of hypoechoic nodules beneath the posterolateral border of the sternocleidomastoid muscle and immediately above the prevertebral fascia. After sterile preparation, a 22-gauge needle is inserted under ultrasound guidance in a lateromedial direction. The needle tip is positioned within the specified space, approximately 2 cm medial to the skin entry point. Following a negative aspiration test, 10 mL of 0.25% levobupivacaine is injected and visualized on the ultrasound screen. The same procedure will be repeated on the contralateral side.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Salivary IL-6 Concentration
Tidsramme: Baseline (preoperatively), 1 hour after the completion of surgery, and 24 hours after the completion of surgery
Unit of measure: pg/mL
Baseline (preoperatively), 1 hour after the completion of surgery, and 24 hours after the completion of surgery
Salivary Cortisol Concentration
Tidsramme: Baseline (preoperatively), 1 hour after the completion of surgery, and 24 hours after the completion of surgery
Unit of measure: nmol/L
Baseline (preoperatively), 1 hour after the completion of surgery, and 24 hours after the completion of surgery
Salivary Alpha-amylase Activity
Tidsramme: Baseline (preoperatively), 1 hour after the completion of surgery, and 24 hours after the completion of surgery
Unit of measure: U/L
Baseline (preoperatively), 1 hour after the completion of surgery, and 24 hours after the completion of surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Intraoperative Sufentanyl Consumption
Tidsramme: Intraoperative period
Unit of measure: mcg/kg/min
Intraoperative period
Total Postoperative Analgetics consumption
Tidsramme: During the first 24 hours after the completion of surgery
Unit of measure: mg
During the first 24 hours after the completion of surgery
Time to Rescue Analgesia
Tidsramme: During the first 24 hours after the completion of surgery
Unit of measure: minutes
During the first 24 hours after the completion of surgery
Hemodynamic Stability (heart rate)
Tidsramme: Intraoperative period and during the first 24 hours after the completion of surgery
Heart rate will be recorded during the resaerch period. Unit of measure: beats/minute
Intraoperative period and during the first 24 hours after the completion of surgery
Postoperative Sedation Level
Tidsramme: During the first 4 hours after the completion of surgery
Postoperative seadtion level will be mesured by Richmond Agitation-Sedation Scale ranging from -5 (deepely sedated) to +4 (highly agitated), with 0 being completely alert and calm.
During the first 4 hours after the completion of surgery
Postoperative Nausea and Vomiting
Tidsramme: During the first 24 hours after the completion of surgery
The incidence of postoperative nausea and vomiting will be determined
During the first 24 hours after the completion of surgery
Hemodynamic Stability (blood pressure)
Tidsramme: Intraoperative period and during the first 24 hours after the completion of surgery

Systolic, diastolic and mean arterial pressure will be recorded during the research peroid.

Unit of measure: mmHg

Intraoperative period and during the first 24 hours after the completion of surgery

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of block complication
Tidsramme: From the administration of the block up to 48 hours after the completion of surgery
The incidence of possible complication of the block will be determined.
From the administration of the block up to 48 hours after the completion of surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. august 2026

Primær fullføring (Antatt)

1. februar 2027

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

8. juli 2026

Først innsendt som oppfylte QC-kriteriene

20. juli 2026

Først lagt ut (Faktiske)

23. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 0119-04-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere